
    
      Edoxaban was recently approved by The Turkish Medicines and Medical Devices Agency for the
      prevention of stroke and systemic embolism in adult patients with Nonvalvular Atrial
      Fibrillation (NVAF) with one or more risk factors, such as congestive heart failure,
      hypertension, diabetes mellitus, prior stroke or transient ischemic attack (TIA). Treatment
      of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and
      PE in adults.

      The study will evaluate the safety of Edoxaban in patients diagnosed with AF who are
      currently on Edoxaban therapy for prevention of stroke in routine clinical practice in Turkey
      for stroke prevention up to 1 year following treatment by specialized as well as
      non-specialized physicians in hospital centers.
    
  